Patricia Inácio, PhD, science writer —

In the study “Pembrolizumab-associated sarcoidosis,” researchers described the first case of sarcoidosis after a patient was treated with after Keytruda (pembrolizumab) to inhibit the programmed cell death-1 (PD-1) receptor. The study was published in the JAAD Case Reports journal. Keytruda is a humanized antibody that targets the PD-1…

The study “Immunological Evidence for the Role of Mycobacteria in Sarcoidosis: A Meta-Analysis,” published recently in PLOS One, links some patients with sarcoidosis to the development of the disease and the presence of mycobacterium tuberculosis, which causes tuberculosis. Mycobacterium tuberculosis is the second leading cause of death by infectious disease, preceded only…

Analyzing the bronchoalveolar lavage fluid (called BALF, it is a small sample of the fluid present in the lungs) for the ratio of immune CD4 and CD8 cells may improve the diagnosis of sarcoidosis, according to the results of a recent study. BALF is collected through a medical procedure using a bronchoscope that is…

For patients with sarcoidosis, high levels of inflammatory markers may predict systemic hypertension (sHTN), high blood pressure in the systemic arteries that carry blood from the heart to the body’s tissues — but little was known about the relationship, until recently. The study, “The Association between ESR and CRP and Systemic Hypertension…